Anti-Human TRAIL-R2 Recombinant Antibody (Lexatumumab) (CAT#: TAB-195)
Recombinant monoclonal antibody to TRAIL-R2. Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.
Specific Inquiry
Figure 1 Cleaved caspase 8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.
Immunoprecipitation assays of mapatumumab (Mapa) or lexatumumab (Lexa) were performed in LP1, MDN, NCI-H929 cells. Cells (20 x 106) were incubated with or without (control) 10ug/ml of mapatumumab (45min) or lexatumumab (90 min) at 37°C in RPMI1640 containing 5% FCS. For NCIH929, cells were pretreated 2h with 2.5uM nutlin3a (N) before addition of lexatumumab. The lysates were immunoprecipitated with a mix of proteins A and G (2 mg of lysate proteins were immunoprecipitated in each assay). For untreated cells, IP was performed after addition of mapatumumab or lexatumumab to the lysates. The immunoprecipitates were analyzed for the presence of the indicated proteins by immunoblot analysis. Input: lysates of untreated or treated cells, Ct IP: immunoprecipitation of control lysates (untreated cells), IP: immunoprecipitation of lysates obtained from cells treated with mapatumumab or lexatumumab. * indicates heavy chain of mapatumumab or lexatumumab.
Surget, S., Chiron, D., Gomez-Bougie, P., Descamps, G., Ménoret, E., Bataille, R., ... & Pellat-Deceunynck, C. (2012). Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer research, canres-0487.
Figure 2 TGFβ1 inhibits apoptotic signaling of TRAIL-R1.
Cells were treated for 24 h with Mapatumumab (10μg/ml, Mapa), Lexatumumab (10μg/ml, Lexa), with or without pre-incubation with TGFβ1 (10 ng/ml for 72 h). Cell death was determined by PI-staining followed byflow cytometric analysis. (A) or by measurements of ATP content using the commercial CellTiter-Glo Luminescent Cell Viability Assay (B). Induction ratio shown in (A) (Mapa or Lexa treatment/respective control) is indicated below the histograms as fold of induction. Data depicted in A) and B) are shown as mean ± SEM of three independent experiments. *pb0.05, n.s. non-significant. (C) Cells were treated for 24 h with Mapa (10μg/ml), Lexa (10μg/ml), or with TRAIL (50 ng/ml) with or without pre-incubation with TGFβ1 (10 ng/ml for 72 h). Analysis of the apoptotic signaling cascade was performed on whole cell lysates by Western blot using antibodies against caspase 8, Bid and caspase 3. For the control of the gel loading,β-actin levels were determined in parallel.
Radke, D. I., Ungefroren, H., Helm, O., Voigt, S., Alp, G., Braun, H., ... & Kalthoff, H. (2016). Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1. Cellular signalling, 28(11), 1652-1662.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- IgG1 - lambda
- Specificity
- Tested positive against native human antigen.
- Species Reactivity
- Human
- Applications
- ELISA, IP, FC, FuncS, Neut, IF, ICC
- CAS
- 845816-02-6
- Generic Name
- Lexatumumab
- UNII
- 967Q0SJD77
- MW
- 143.6 kDa
- Related Disease
- Cancers
Product Property
- Purity
- >95.0% as determined by analysis by SDS-PAGE.
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- The TNFRSF10B antibody has been reported in applications of IP, WB.
Target
- Alternative Names
- Lexatumumab;845816-02-6;ETR2-ST01;HGS-ETR2;HGS1018;ETR2-ST01;TNFRSF10B;tumor necrosis factor receptor superfamily, member 10b;tumor necrosis factor receptor superfamily member 10B;CD262;DR5;KILLER;TRAIL R2;TRICK2A;TRICKB;Fas-like protein;death receptor 5;
- Gene ID
- 8795
- UniProt ID
- O14763
Related Resources
Please refer to Lexatumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lexatumumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Lexatumumab"
Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Lexatumumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TRAIL-R2. Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.
See other products for "TNFRSF10B"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody
Humanized Antibody
Rat Antibody
Recombinant Antibody
Mouse Antibody
Human Antibody
Rabbit Monoclonal Antibody
Agonistic Antibody
scFv Fragment Antibody
ADCC Enhanced Antibody
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NABL-052 | Recombinant Anti-human TNFRSF10B VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
| HPAB-0703-YJ-VHH | Camelid Anti-TNFRSF10B Recombinant Single Domain Antibody (HPAB-0703-YJ-VHH) | ELISA, Apop | Camelid VHH |
| HPAB-0704-YJ-VHH | Camelid Anti-TNFRSF10B Recombinant Single Domain Antibody (HPAB-0704-YJ-VHH) | ELISA | Camelid VHH |
Customer Reviews and Q&As
Customer Review
Q&As
-
Excellent for TRAIL-R2 Research
The Anti-Human TRAIL-R2 Therapeutic Antibody (Lexatumumab) has been excellent for our TRAIL-R2 studies. Its specificity and sensitivity are outstanding, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time. -
Effective and Dependable
We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for TRAIL-R2 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab. -
Consistent High-Quality Results
This antibody has proven to be consistent and dependable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for TRAIL-R2 have been particularly beneficial.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-195, RRID: AB_3111865)
Copy citation
Popular products with customers
Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: WB, FC, IP, ELISA, Neut, FuncS, IF
Application: Neut, ELISA, FuncS
-1.png)
Application: IB, ELISA, FC, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: Inhib, ELISA, FC, FuncS
-1.jpg)
Application: FC
Application: ELISA, FuncS, Neut, IF, WB, EM, Inhib, IHC
Application: ELISA, Cyt, PP, Inhib
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
